Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors
Amin H. Nassar(Brigham and Women's Hospital), Alexander Gusev(Dana-Farber Cancer Institute), Adam J. Schoenfeld(Memorial Sloan Kettering Cancer Center), Kanika Arora(Memorial Sloan Kettering Cancer Center), Guruprasad Ananda(Dana-Farber Cancer Institute), Stefan Groha(Dana-Farber Cancer Institute), Tomin Perea-Chamblee(Memorial Sloan Kettering Cancer Center), Talal El Zarif(Yale University), Jian Carrot‐Zhang(Memorial Sloan Kettering Cancer Center), Nikolaus Schultz(Memorial Sloan Kettering Cancer Center), Michael F. Berger(Memorial Sloan Kettering Cancer Center), Christopher J. Fong(Memorial Sloan Kettering Cancer Center), Habib El‐Khoury(Dana-Farber Cancer Institute), Marios Giannakis(Broad Institute), Guru Sonpavde(AdventHealth Orlando), Toni K. Choueiri(Harvard University), Pier Vitale Nuzzo(Dana-Farber Cancer Institute), Tarek H. Mouhieddine(Icahn School of Medicine at Mount Sinai), Noah Zaitlen(University of California, Los Angeles), Wenxin Xu(Dana-Farber Cancer Institute), Elio Adib(Dana-Farber Brigham Cancer Center), Muhieddine Labban(Brigham and Women's Hospital), Kent W. Mouw(Massachusetts General Hospital), Kodi Taraszka(University of California, Los Angeles), Robert I. Haddad(Georgetown University), F. Stephen Hodi(Harvard University), Deborah Schrag(Dana-Farber Brigham Cancer Center), Laura E. MacConaill(Brigham and Women's Hospital), David J. Kwiatkowski(Brigham and Women's Hospital), Sarah Abou Alaiwi(Yale New Haven Hospital), Elie W. Akl(Brigham and Women's Hospital), Chris Labaki(Beth Israel Deaconess Medical Center)
Cited by 117
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.5k
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k